Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 10, Number 7—July 2004


Collecting Data To Assess SARS Interventions

R. Douglas Scott*Comments to Author , Edward W. Gregg*, and Martin I. Meltzer*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Cite This Article


Highlight and copy the desired format.

EID Scott R, Gregg EW, Meltzer MI. Collecting Data To Assess SARS Interventions. Emerg Infect Dis. 2004;10(7):1290-1292.
AMA Scott R, Gregg EW, Meltzer MI. Collecting Data To Assess SARS Interventions. Emerging Infectious Diseases. 2004;10(7):1290-1292. doi:10.3201/eid1007.030749.
APA Scott, R., Gregg, E. W., & Meltzer, M. I. (2004). Collecting Data To Assess SARS Interventions. Emerging Infectious Diseases, 10(7), 1290-1292.


With cases of severe acute respiratory syndrome (SARS) occurring across geographic regions, data collection on the effectiveness of intervention strategies should be standardized to facilitate analysis. We propose a minimum dataset to capture data needed to examine the basic reproduction rate, case status and criteria, symptoms, and outcomes of SARS.

First detected in China, confirmed and probable cases of severe acute respiratory syndrome (SARS) have now appeared in at least 30 countries in five continents. SARS is the first new severe infectious disease to occur in the 21st century, and little is known about its epidemiologic features (1). To assess the effect of SARS on public health and outcomes, data are needed about who becomes ill, how they contracted their illness, and the sequelae.

A minimum set of data on intervention effectiveness should be collected in a uniform manner from each identified SARS case-patient at each location. Without such standardization, datasets from different locales may not be sufficiently comparable, thereby limiting the ability to scientifically evaluate both the effect of SARS and the interventions to control and prevent its spread.

We propose a minimum set of epidemiologic and clinical variables that should be among the top priorities when designing data collection protocols related to SARS interventions. We set priorities for the variables in the minimum dataset as a guide for agencies unable to collect all the recommended data. Additionally, we summarize the health measures constructed from each of the variables, along with the possible policy implications, to provide further guidance to health agencies regarding the importance of each variable. A case study is presented in Appendix.

Previous tools have been used to understand the spread of SARS and associated illnesses (2). These tools have not provided all necessary data to facilitate modeling usefulness and cost-effectiveness of interventions. Researchers have published results from relevant epidemiologic data, but no forms of itemized data are readily available (3). Our minimum dataset differs from minimum reporting requirements recently published by the World Health Organization (WHO) (2). WHO data templates include a daily summary of SARS cases to be reported at the national level and a case-reporting form that contains detailed clinical information (based on current WHO case definitions), including patient demographics, exposure, contact follow-up, daily reporting of symptoms, hospital admission, final case classification, and final case status. The dataset we propose captures information on length of exposure, incubation period from exposure to symptom onset, and use of health care resources (e.g., length of hospitalization, length of isolation, and admission to intensive care) not currently collected by WHO's template.

Proposed Minimum Dataset and Data Prioritization

Figure 1

Thumbnail of Schematic of table illustrating the epidemiologic data needed to evaluate impact of SARS and interventions: data relating to exposures and date of onset of symptoms. Data entry columns allow for multiple exposures and can expand as needed. Suggestions for coding the data for this table are given in Table A1. Note: to download this table for use, see PDF version.

Figure 1. . Schematic of table illustrating the epidemiologic data needed to evaluate impact of SARS and interventions: data relating to exposures and date of onset of symptoms. Data entry columns allow for...

Figure 2

Thumbnail of Schematic of table illustrating the epidemiologic data needed to evaluate impact of SARS and interventions: data relating to case status and outcomes. Suggestions for coding the data for this table are given in Table A2. Data entry columns move according to footnotes in Table A2 (letters at top of each column are used in describing data and rationale for each data point). Note: to download this table for use, see PDF version.

Figure 2. . Schematic of table illustrating the epidemiologic data needed to evaluate impact of SARS and interventions: data relating to case status and outcomes. Suggestions for coding the data for this table...

Figures 1 and 2 illustrate the minimum epidemiologic variables needed to evaluate the public health effect of SARS and the cost of interventions. These data would provide the evidence to determine key epidemiologic relationships, including the incubation period (time from exposure to onset of symptoms), the onset of symptoms leading to hospitalization, and the outcomes resulting from treatment (either discharge of patient or death). Descriptions of the variables listed in Figures 1 and 2, along with suggestions for coding, are provided in Tables A1 and A2. For all tables, the column heading corresponds with the variable name (e.g., A represents the case identification [ID] number, B represents sex, C represents age).

Figure 1 captures case-patient demographics, exposures, and symptoms. Suggested coding for demographic variables (Tables A1 and A2) include patient ID and age as continuous variables and sex and coexisting conditions (e.g., cardiovascular disease, diabetes) or syndromes (HIV/AIDS) as categorical variables. Other categories for coexisting conditions can be added as appropriate (e.g., smoking). An important distinction should be made between patients who have no known diagnosed coexisting conditions (coded as none known) as opposed to patients for whom information about coexisting conditions is not available or missing (coded as unknown).

In Figure 1, exposure variables and their suggested coding include date (DD/MM/YY), source (whether the source is already identified and included in the data table as an observed patient with an assigned ID or whether the source is unknown), duration of exposure (<30 minutes, 30–59 minutes, or >60 minutes), and locale (whether exposure occurred at home, in a hospital, or some other location). The same variables are measured for each exposure, and the table can be expanded to collect information on all known exposures.

Symptoms are categorized as either respiratory or nonrespiratory. For each symptom, onset date and type (a categorical variable that can be expanded for patients with multiple symptoms) are collected. Suggested categories for symptoms include fever, myalgia, dyspnea, headache, chills, diarrhea, nausea, sore throat, arthralgia, chest pain, productive cough, nonheadache neurologic symptoms (e.g., dizziness), rhinorrhea or runny nose, vomiting, and abdominal pain. The list of symptom categories can be revised or extended as needed.

Figure 2 contains information on case criteria, along with health outcomes associated with the case. Categorical variables making up case status include the clinical case criteria (either asymptomatic or mild respiratory illness, moderate illness, severe respiratory illness, or none), epidemiologic criteria (travel within 10 days to infected area, close contact, both, or none), laboratory confirmation (yes, no, or undetermined), and case classification (probable, suspected, or noncase).

Outcome variables include hospitalization (along with admission date if hospitalized), treatment status (antiviral agent, antibacterial agent, or other treatment), isolation start date, number of days isolated (a continuous variable), number of days on ventilation or in intensive care (continuous variables), discharge date (0 if still hospitalized), death (yes or no), and date of death. Appendix provides an example of Figures 1 and 2 filled out with data from four "typical" case-patients. The variable categories from Table A1 can be readily extended or revised as new information about SARS becomes available. The footnotes offer the definitions that served as the basis for the suggested categories.

Priority Classification Groups

Tables A1 and A2 also provide proposed priority classification groups for each variable listed in Figures 1 and 2. Variables that are labeled "priority group 1" represent the most important set of variables, and those labeled as "priority group 3," the least important. The Table provides a summary of how each variable contributes to important health policy questions related to the SARS outbreak. Taken together, these tables can provide guidance to health organizations regarding which data should be collected so that the needed policy analysis can be conducted.

Priority group 1 variables (sex, age, date and source of exposure, date of symptom onset, and case status and criteria variables) contain the information on the transmission rate of the disease and incubation periods. These variables provide crucial information in determining the basic reproduction number of an infection (defined as the expected number of secondary infectious cases resulting from one primary case in a susceptible population) (4,5). This measure is vital for estimating the impact of control measures to reduce the transmission of SARS (4,5). Priority group 2 variables (duration and locale of exposure; hospitalization, including start date; isolation, including start date; and death, including date of death) provide information that can be used to evaluate the risk for hospitalization or death associated with exposure, length of incubation, and impact of isolation. Priority group 3 variables (coexisting conditions; categories of symptoms; treatment status; ventilation or intensive care, including start date; and date of discharge) are not essential information for containing SARS outbreaks but provide additional information about healthcare resources (treatment and intensive care) used to treat SARS patients. Priority group 3 variables can also be used by hospital administrators and public health officials to plan and prepare for a sudden change in resource use during a catastrophic infectious disease outbreak (e.g., pandemic influenza) (6).


The emergence of a novel disease like SARS, which requires a global public health response to contain its spread, has illustrated the need for collecting effectiveness data in a uniform manner. Given the potential for a large variation in location-specific circumstances, producing a single questionnaire that would be entirely suitable for all locales would be difficult. Figures 1 and 2 illustrate some of the most important data needed to understand and control the disease. The tables present a standardized protocol and approach for ensuring that all the proposed data have been collected. As an illustration of the use of the tables, a case study is presented in Tables A3 and A4. Identifying effective interventions during an outbreak becomes important in managing public health resources. The minimum dataset proposed here provides a basis for standardizing the collection of data from various geographic locations, thereby facilitating the analysis of SARS interventions.


Example Data (entries in Tables A1 and A2)
Hypothetical Patient 1

A 55-year-old man traveled to mainland China from March 5 to March 15. By March 18, the man had a temperature of 38.5°C, cough, and sore throat. He was hospitalized on March 20, and results from radiographic tests indicated pneumonia. The patient was given a course of antimicrobial drugs, and the fever resolved. By March 23, the patient began complaining of chest pains and had difficulty breathing. At this point, SARS was suspected, and the patient was moved into isolation in an intensive care unit the same day and had to be intubated for 5 days. Results from the polymerase chain reaction (PCR) test indicated the presence of the SARS-associated coronavirus. The patient began antiviral treatment and remained isolated in intensive care until April 14. Infection resolved, and the patient was discharged on April 16. The patient had no previous history of serious respiratory illness or any other serious coexisting conditions, and the source of the exposure could not be determined.

Hypothetical Patient 2

The 50-year-old wife of patient 1 was exposed to SARS upon her husband's return on March 15. On March 23, a cough developed, and she had shortness of breath and chills. She was hospitalized on March 24 with a temperature of 38.1°C. Radiographic tests indicated evidence of pneumonia. Because SARS was suspected, the patient was placed on antiviral treatment, and SARS was confirmed by PCR testing. Patient 2 was placed in isolation on a medical ward on March 25 and remained there until April 11. She was discharged on April 12. This patient was also diabetic.

Hypothetical Patient 3

The 15-year-old daughter of patients 1 and 2 also became exposed to SARS when her father returned on March 15. She has a mild asthma condition. On March 23, she complained of stomach pain and, upon examination, had a temperature of 37.7°C. She was hospitalized on March 25 for observation, but no further symptoms developed. PCR testing returned negative results for the SARS coronavirus. Her fever resolved, and she was released on March 27.

Hypothetical Patient 4

The 23-year-old daughter of patients 1 and 2, who lived away the family home, became exposed to SARS through contact with both patients 1 and 2 upon a brief visit (lasting <1 hour) on March 19. By March 27, she had a cough and a temperature of 38.1°C. She contacted her physician and was hospitalized on March 28 for observation and evaluation. Results of radiographic testing did not show pneumonia. She began an antiviral treatment program and began to improve. A PCR test was not completed because her fever resolved, and no other symptoms developed. She was discharged on April 1.

Dr. Scott is an economist with the Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. His areas of research include the economics of hospital infection control, infectious diseases, and patient safety.


  1. World Health Organization. Consensus document on the epidemiology of severe acute respiratory syndrome (SARS). [Cited June 04, 2004]. Available from:
  2. Global surveillance for severe acute respiratory syndrome (SARS). Wkly Epidemiol Rec. 2003;78:10019.PubMed
  3. Donnelly CA, Ghani AC, Leung GM, Hedley AJ, Fraser C, Riley S, Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet. 2003;361:17616. DOIPubMed
  4. Lipsitch M, Cohen T, Cooper B, Robins JM, Ma S, James L, Transmission dynamics and control of severe acute respiratory syndrome. Science. 2003;300:196670. DOIPubMed
  5. Riley S, Fraser C, Donnelly C, Ghani AC, Abu-Raddad LJ, Hedley AJ, Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions. Science. 2003;300:19616. DOIPubMed
  6. Gensheimer KF, Meltzer MI, Postema AS, Strikas RA. Influenza pandemic preparedness. Emerg Infect Dis. 2003;9:16458.PubMed



Cite This Article

DOI: 10.3201/eid1007.030749

Table of Contents – Volume 10, Number 7—July 2004


Please use the form below to submit correspondence to the authors or contact them at the following address:

R. Douglas Scott II, Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Mailstop E55, 1600 Clifton Rd., Atlanta, GA 30333, USA; fax: 404-498-1101

character(s) remaining.

Comment submitted successfully, thank you for your feedback.